New Textbook “Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development” Provides Critical Review of Current and Emerging Clinical Investigation Methods

New Textbook “Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development” Provides Critical Review of Current and Emerging Clinical Investigation Methods

With contributions from world-renowned experts in metabolism,  the textbook is the first to extensively analyze and illustrate techniques for use in early phase clinical studies of new drugs for diabetes, obesity and related cardiometabolic disease

2015-Translational Research TextbookSAN DIEGO, January 22, 2015 /PRNewswire/ – ProSciento, Inc., a clinical research organization (CRO) focused on diabetes and obesity, announced today a new textbook, Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development, edited by ProSciento senior scientists Prof. Andrew Krentz, Prof. Lutz Heinemann and Dr. Marcus Hompesch and published by Springer, a leading global scientific publisher.

The textbook is the first to extensively analyze and illustrate techniques for use in early phase clinical studies of new drugs for diabetes, obesity and related cardiometabolic disease.  The first portion of the book involving several chapters is a critical review of current clinical investigation methodologies.  Each chapter focuses on a specific approach or methodology, written by a leading expert providing practical applications and scrutinizing pros and cons.  The second portion of the book details emerging and complementary research methods, as well as related ethical and regulatory considerations.

Authors include scientists from ProSciento; Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt; Image Reading Center, Inc.; Kinexum, Inc.; Kinmed, Inc.; Maastricht University Medical Centre; National Institutes of Health; University of California, San Diego; and University of Florida, Orlando. A list of chapters and authors is available on the Springer website.

“The editors of this book are all highly experienced experts in academic research and drug development, and they have recruited world leaders in metabolic research to cover a range of topics.  Each chapter focuses on a specific approach or methodology, representing the leading edge of knowledge in clinical research and early stage drug development,” said Jerrold M. Olefsky, MD, University of California, San Diego, Professor of Medicine, Associate Dean for Scientific Affairs. “The textbook will be a valuable resource to anyone in the field of early phase metabolic research, as well as clinicians practicing in these specialties.”

The textbook is available in hardcover and electronic formats, and individual chapters can be downloaded at springer.com; amazon.com; and other textbook distributors.

About ProSciento, Inc.

ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
abby.devine@prosciento.com

For business development inquires:
bd@prosciento.com

For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com